{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,17]],"date-time":"2026-08-17T18:25:06Z","timestamp":1786991106890,"version":"build-2736575974"},"reference-count":166,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2025,10,1]],"date-time":"2025-10-01T00:00:00Z","timestamp":1759276800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2025,10,1]],"date-time":"2025-10-01T00:00:00Z","timestamp":1759276800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2025,10,1]],"date-time":"2025-10-01T00:00:00Z","timestamp":1759276800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2025,10,1]],"date-time":"2025-10-01T00:00:00Z","timestamp":1759276800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2025,10,1]],"date-time":"2025-10-01T00:00:00Z","timestamp":1759276800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2025,10,1]],"date-time":"2025-10-01T00:00:00Z","timestamp":1759276800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2025,10,1]],"date-time":"2025-10-01T00:00:00Z","timestamp":1759276800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"funder":[{"DOI":"10.13039\/100017956","name":"Health Commission of Gansu Province","doi-asserted-by":"publisher","award":["GSWSZD2025-01"],"award-info":[{"award-number":["GSWSZD2025-01"]}],"id":[{"id":"10.13039\/100017956","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100018554","name":"Science and Technology Program of Gansu Province","doi-asserted-by":"publisher","award":["23JRRA0953"],"award-info":[{"award-number":["23JRRA0953"]}],"id":[{"id":"10.13039\/501100018554","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100013076","name":"National Major Science and Technology Projects of China","doi-asserted-by":"publisher","award":["25ZDFA005"],"award-info":[{"award-number":["25ZDFA005"]}],"id":[{"id":"10.13039\/501100013076","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["International Immunopharmacology"],"published-print":{"date-parts":[[2025,10]]},"DOI":"10.1016\/j.intimp.2025.115397","type":"journal-article","created":{"date-parts":[[2025,8,23]],"date-time":"2025-08-23T00:12:47Z","timestamp":1755907967000},"page":"115397","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":4,"special_numbering":"C","title":["Cancer therapy\u2013induced cardiac metabolic reprogramming: A new frontier in cardio-oncology"],"prefix":"10.1016","volume":"164","author":[{"given":"Zekun","family":"Lang","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jing","family":"Zhao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kang","family":"Dong","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yanhang","family":"Zhao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lu","family":"Bai","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Qianyue","family":"Cong","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Cheng","family":"Chen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yongxiang","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jianming","family":"Tang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ming","family":"Bai","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"9","key":"10.1016\/j.intimp.2025.115397_bb0005","doi-asserted-by":"crossref","first-page":"2278","DOI":"10.1093\/annonc\/mdt182","article-title":"Pertuzumab plus trastuzumab in combination with standard neoadjuvant anthracycline-containing and anthracycline-free chemotherapy regimens in patients with HER2-positive early breast cancer: a randomized phase II cardiac safety study (TRYPHAENA)","volume":"24","author":"Schneeweiss","year":"2013","journal-title":"Ann. Oncol."},{"issue":"1","key":"10.1016\/j.intimp.2025.115397_bb0010","doi-asserted-by":"crossref","first-page":"252","DOI":"10.1186\/s12916-024-03474-0","article-title":"Taxane combined with lobaplatin or anthracycline for neoadjuvant chemotherapy of triple-negative breast cancer: a randomized, controlled, phase II study","volume":"22","author":"Wang","year":"2024","journal-title":"BMC Med."},{"issue":"2","key":"10.1016\/j.intimp.2025.115397_bb0015","doi-asserted-by":"crossref","DOI":"10.1001\/jamanetworkopen.2022.54669","article-title":"Association of Anthracycline with Heart Failure in patients treated for breast Cancer or lymphoma, 1985-2010","volume":"6","author":"Larsen","year":"2023","journal-title":"JAMA Netw. Open"},{"issue":"8","key":"10.1016\/j.intimp.2025.115397_bb0020","doi-asserted-by":"crossref","first-page":"1038","DOI":"10.1007\/s11864-024-01238-9","article-title":"Precision treatment of anthracycline-induced cardiotoxicity: An updated review","volume":"25","author":"Kuang","year":"2024","journal-title":"Curr. Treat. Options Oncol."},{"issue":"11","key":"10.1016\/j.intimp.2025.115397_bb0025","doi-asserted-by":"crossref","first-page":"568","DOI":"10.1007\/s00018-022-04605-7","article-title":"Anthracycline-induced cardiotoxicity and cell senescence: new therapeutic option?","volume":"79","author":"Seara","year":"2022","journal-title":"Cell. Mol. Life Sci."},{"issue":"3","key":"10.1016\/j.intimp.2025.115397_bb0030","doi-asserted-by":"crossref","DOI":"10.1161\/CIRCHEARTFAILURE.119.005910","article-title":"Anthracycline cardiotoxicity","volume":"12","author":"Narezkina","year":"2019","journal-title":"Circ. Heart Fail."},{"issue":"12","key":"10.1016\/j.intimp.2025.115397_bb0035","doi-asserted-by":"crossref","first-page":"1765","DOI":"10.1007\/s11912-022-01329-6","article-title":"Cardio-oncology in childhood: state of the art","volume":"24","author":"Bennati","year":"2022","journal-title":"Curr. Oncol. Rep."},{"issue":"8","key":"10.1016\/j.intimp.2025.115397_bb0040","doi-asserted-by":"crossref","first-page":"817","DOI":"10.1080\/17425255.2017.1351547","article-title":"Chemotherapy-induced cardiotoxicity in children","volume":"13","author":"Bansal","year":"2017","journal-title":"Expert Opin. Drug Metab. Toxicol."},{"issue":"4","key":"10.1016\/j.intimp.2025.115397_bb0045","doi-asserted-by":"crossref","first-page":"881","DOI":"10.1007\/s10741-020-10063-9","article-title":"Oxidative stress and inflammation: determinants of anthracycline cardiotoxicity and possible therapeutic targets","volume":"26","author":"Fabiani","year":"2021","journal-title":"Heart Fail. Rev."},{"issue":"2","key":"10.1016\/j.intimp.2025.115397_bb0050","doi-asserted-by":"crossref","first-page":"760","DOI":"10.7150\/ijbs.65258","article-title":"Underlying the mechanisms of doxorubicin-induced acute cardiotoxicity: oxidative stress and cell death","volume":"18","author":"Kong","year":"2022","journal-title":"Int. J. Biol. Sci."},{"key":"10.1016\/j.intimp.2025.115397_bb0055","doi-asserted-by":"crossref","first-page":"41","DOI":"10.1016\/j.toxlet.2019.02.013","article-title":"Oxidative stress injury in doxorubicin-induced cardiotoxicity","volume":"307","author":"Songbo","year":"2019","journal-title":"Toxicol. Lett."},{"issue":"22","key":"10.1016\/j.intimp.2025.115397_bb0060","doi-asserted-by":"crossref","DOI":"10.3390\/ijms252212223","article-title":"Metabolic reprogramming of immune cells in the tumor microenvironment","volume":"25","author":"Wang","year":"2024","journal-title":"Int. J. Mol. Sci."},{"issue":"1","key":"10.1016\/j.intimp.2025.115397_bb0065","doi-asserted-by":"crossref","first-page":"114","DOI":"10.1038\/s41392-023-01378-8","article-title":"Metabolic landscape in cardiac aging: insights into molecular biology and therapeutic implications","volume":"8","author":"Xie","year":"2023","journal-title":"Signal Transduct. Target. Ther."},{"key":"10.1016\/j.intimp.2025.115397_bb0070","doi-asserted-by":"crossref","DOI":"10.1016\/j.redox.2022.102446","article-title":"LDHA-mediated metabolic reprogramming promoted cardiomyocyte proliferation by alleviating ROS and inducing M2 macrophage polarization","volume":"56","author":"Chen","year":"2022","journal-title":"Redox Biol."},{"key":"10.1016\/j.intimp.2025.115397_bb0075","doi-asserted-by":"crossref","DOI":"10.3389\/fphys.2022.831829","article-title":"New insights into energy substrate utilization and metabolic remodeling in cardiac physiological adaption","volume":"13","author":"Shi","year":"2022","journal-title":"Front. Physiol."},{"key":"10.1016\/j.intimp.2025.115397_bb0080","doi-asserted-by":"crossref","first-page":"e209","DOI":"10.5114\/amsad.2021.112475","article-title":"Ketone bodies and the heart","volume":"6","author":"Papazafiropoulou","year":"2021","journal-title":"Arch Med Sci Atheroscler Dis"},{"issue":"1","key":"10.1016\/j.intimp.2025.115397_bb0085","doi-asserted-by":"crossref","first-page":"69","DOI":"10.1038\/s41392-025-02141-x","article-title":"Energy metabolism in health and diseases","volume":"10","author":"Liu","year":"2025","journal-title":"Signal Transduct. Target. Ther."},{"issue":"1","key":"10.1016\/j.intimp.2025.115397_bb0090","doi-asserted-by":"crossref","first-page":"196","DOI":"10.1186\/s12967-024-04942-0","article-title":"ACACA reduces lipid accumulation through dual regulation of lipid metabolism and mitochondrial function via AMPK- PPAR\u03b1- CPT1A axis","volume":"22","author":"Dong","year":"2024","journal-title":"J. Transl. Med."},{"key":"10.1016\/j.intimp.2025.115397_bb0095","doi-asserted-by":"crossref","DOI":"10.1016\/j.molmet.2023.101694","article-title":"Mitochondrial pyruvate carrier inhibition initiates metabolic crosstalk to stimulate branched chain amino acid catabolism","volume":"70","author":"Ferguson","year":"2023","journal-title":"Mol Metab"},{"issue":"7","key":"10.1016\/j.intimp.2025.115397_bb0100","doi-asserted-by":"crossref","DOI":"10.3390\/ijms23074022","article-title":"The critical role of the branched chain amino acids (BCAAs) catabolism-regulating enzymes, branched-chain aminotransferase (BCAT) and branched-chain \u03b1-keto acid dehydrogenase (BCKD), in human pathophysiology","volume":"23","author":"Dimou","year":"2022","journal-title":"Int. J. Mol. Sci."},{"issue":"6","key":"10.1016\/j.intimp.2025.115397_bb0105","first-page":"670","article-title":"The anthracyclines: will we ever find a better doxorubicin?","volume":"19","author":"Weiss","year":"1992","journal-title":"Semin. Oncol."},{"issue":"23","key":"10.1016\/j.intimp.2025.115397_bb0110","doi-asserted-by":"crossref","first-page":"2323","DOI":"10.2217\/fon-2018-0047","article-title":"Aldoxorubicin therapy for the treatment of patients with advanced soft tissue sarcoma","volume":"14","author":"Seetharam","year":"2018","journal-title":"Future Oncol."},{"issue":"5","key":"10.1016\/j.intimp.2025.115397_bb0115","doi-asserted-by":"crossref","first-page":"432","DOI":"10.2174\/1389450116666150416115852","article-title":"Doxorubicin action on mitochondria: relevance to osteosarcoma therapy?","volume":"19","author":"Armstrong","year":"2018","journal-title":"Curr. Drug Targets"},{"issue":"1","key":"10.1016\/j.intimp.2025.115397_bb0120","doi-asserted-by":"crossref","first-page":"102","DOI":"10.1007\/s13346-024-01648-0","article-title":"A comprehensive review on doxorubicin: mechanisms, toxicity, clinical trials, combination therapies and nanoformulations in breast cancer","volume":"15","author":"Bisht","year":"2025","journal-title":"Drug Deliv. Transl. Res."},{"issue":"2","key":"10.1016\/j.intimp.2025.115397_bb0125","doi-asserted-by":"crossref","first-page":"193","DOI":"10.7164\/antibiotics.41.193","article-title":"Synthesis and antileukemic activity of N-enamine derivatives of daunorubicin, 5-iminodaunorubicin, and doxorubicin","volume":"41","author":"Stefa\u0144ska","year":"1988","journal-title":"J. Antibiot. (Tokyo)"},{"issue":"5","key":"10.1016\/j.intimp.2025.115397_bb0130","doi-asserted-by":"crossref","first-page":"559","DOI":"10.1007\/BF02125741","article-title":"Doxorubicin concentrations in plasma and myocardium and their respective roles in cardiotoxicity","volume":"1","author":"Timour","year":"1988","journal-title":"Cardiovasc. Drugs Ther."},{"issue":"3","key":"10.1016\/j.intimp.2025.115397_bb0135","doi-asserted-by":"crossref","first-page":"975","DOI":"10.1111\/j.1476-5381.1993.tb13909.x","article-title":"Time-related increases in cardiac concentrations of doxorubicinol could interact with doxorubicin to depress myocardial contractile function","volume":"110","author":"Mushlin","year":"1993","journal-title":"Br. J. Pharmacol."},{"issue":"15","key":"10.1016\/j.intimp.2025.115397_bb0140","doi-asserted-by":"crossref","first-page":"1081","DOI":"10.1089\/ars.2020.8016","article-title":"Cardiac damage in anthracyclines therapy: focus on oxidative stress and inflammation","volume":"32","author":"Rocca","year":"2020","journal-title":"Antioxid. Redox Signal."},{"issue":"1","key":"10.1016\/j.intimp.2025.115397_bb0145","doi-asserted-by":"crossref","first-page":"295","DOI":"10.1007\/s10741-020-09977-1","article-title":"Anthracycline-induced cardiotoxicity and renin-angiotensin-aldosterone system-from molecular mechanisms to therapeutic applications","volume":"27","author":"Sobczuk","year":"2022","journal-title":"Heart Fail. Rev."},{"issue":"3","key":"10.1016\/j.intimp.2025.115397_bb0150","doi-asserted-by":"crossref","first-page":"375","DOI":"10.1007\/s10637-017-0443-2","article-title":"Metabolic carbonyl reduction of anthracyclines - role in cardiotoxicity and cancer resistance. Reducing enzymes as putative targets for novel cardioprotective and chemosensitizing agents","volume":"35","author":"Piska","year":"2017","journal-title":"Invest. New Drugs"},{"issue":"1","key":"10.1016\/j.intimp.2025.115397_bb0155","doi-asserted-by":"crossref","first-page":"823","DOI":"10.1186\/s12967-023-04715-1","article-title":"WGX50 mitigates doxorubicin-induced cardiotoxicity through inhibition of mitochondrial ROS and ferroptosis","volume":"21","author":"Tai","year":"2023","journal-title":"J. Transl. Med."},{"issue":"36","key":"10.1016\/j.intimp.2025.115397_bb0160","doi-asserted-by":"crossref","DOI":"10.1073\/pnas.2117396119","article-title":"Mitochondrial outer membrane protein FUNDC2 promotes ferroptosis and contributes to doxorubicin-induced cardiomyopathy","volume":"119","author":"Ta","year":"2022","journal-title":"Proc. Natl. Acad. Sci. U. S. A."},{"issue":"11","key":"10.1016\/j.intimp.2025.115397_bb0165","doi-asserted-by":"crossref","first-page":"783","DOI":"10.1056\/NEJM200103153441101","article-title":"Use of chemotherapy plus a monoclonal antibody against HER2 for metastatic breast cancer that overexpresses HER2","volume":"344","author":"Slamon","year":"2001","journal-title":"N. Engl. J. Med."},{"issue":"5","key":"10.1016\/j.intimp.2025.115397_bb0170","doi-asserted-by":"crossref","first-page":"1215","DOI":"10.1200\/JCO.2002.20.5.1215","article-title":"Cardiac dysfunction in the trastuzumab clinical trials experience","volume":"20","author":"Seidman","year":"2002","journal-title":"J. Clin. Oncol."},{"issue":"14","key":"10.1016\/j.intimp.2025.115397_bb0175","doi-asserted-by":"crossref","first-page":"1273","DOI":"10.1056\/NEJMoa0910383","article-title":"Adjuvant trastuzumab in HER2-positive breast cancer","volume":"365","author":"Slamon","year":"2011","journal-title":"N. Engl. J. Med."},{"issue":"4","key":"10.1016\/j.intimp.2025.115397_bb0180","doi-asserted-by":"crossref","first-page":"451","DOI":"10.1097\/HCO.0000000000000637","article-title":"Cardiotoxicity of HER2-targeted therapies","volume":"34","author":"Copeland-Halperin","year":"2019","journal-title":"Curr. Opin. Cardiol."},{"issue":"2","key":"10.1016\/j.intimp.2025.115397_bb0185","doi-asserted-by":"crossref","first-page":"134","DOI":"10.1056\/NEJMoa1406281","article-title":"Adjuvant paclitaxel and trastuzumab for node-negative, HER2-positive breast cancer","volume":"372","author":"Tolaney","year":"2015","journal-title":"N. Engl. J. Med."},{"issue":"1","key":"10.1016\/j.intimp.2025.115397_bb0190","doi-asserted-by":"crossref","first-page":"29","DOI":"10.1001\/jamaoncol.2015.3709","article-title":"Cardiac outcomes of patients receiving adjuvant weekly paclitaxel and Trastuzumab for node-negative, ERBB2-positive breast Cancer","volume":"2","author":"Dang","year":"2016","journal-title":"JAMA Oncol."},{"issue":"1","key":"10.1016\/j.intimp.2025.115397_bb0195","doi-asserted-by":"crossref","first-page":"21","DOI":"10.1007\/s10549-021-06280-x","article-title":"Trastuzumab-induced cardiotoxicity: a review of clinical risk factors, pharmacologic prevention, and cardiotoxicity of other HER2-directed therapies","volume":"188","author":"Dempsey","year":"2021","journal-title":"Breast Cancer Res. Treat."},{"issue":"2","key":"10.1016\/j.intimp.2025.115397_bb0200","doi-asserted-by":"crossref","first-page":"237","DOI":"10.1007\/s10549-019-05303-y","article-title":"HER2+ breast cancer treatment and cardiotoxicity: monitoring and management","volume":"177","author":"Jerusalem","year":"2019","journal-title":"Breast Cancer Res. Treat."},{"issue":"1","key":"10.1016\/j.intimp.2025.115397_bb0205","doi-asserted-by":"crossref","first-page":"44","DOI":"10.1186\/s12964-022-00854-y","article-title":"Tumor immunotherapies by immune checkpoint inhibitors (ICIs); the pros and cons","volume":"20","author":"Naimi","year":"2022","journal-title":"Cell Commun. Signal"},{"issue":"1","key":"10.1016\/j.intimp.2025.115397_bb0210","doi-asserted-by":"crossref","DOI":"10.1161\/JAHA.124.035689","article-title":"Myocarditis in patients starting combination checkpoint inhibitor therapy: analysis of a commercial claims database","volume":"14","author":"Lindsay","year":"2025","journal-title":"J. Am. Heart Assoc."},{"issue":"1","key":"10.1016\/j.intimp.2025.115397_bb0215","first-page":"33","article-title":"Immune checkpoint inhibitors and myocarditis in advanced non-small cell lung cancer: a nationwide cohort study","volume":"11","author":"Li","year":"2025","journal-title":"Cardiooncology"},{"issue":"3","key":"10.1016\/j.intimp.2025.115397_bb0220","doi-asserted-by":"crossref","first-page":"431","DOI":"10.1007\/s12265-020-10042-3","article-title":"The role of biomarkers in cardio-oncology","volume":"13","author":"Ananthan","year":"2020","journal-title":"J. Cardiovasc. Transl. Res."},{"issue":"5","key":"10.1016\/j.intimp.2025.115397_bb0225","doi-asserted-by":"crossref","first-page":"36","DOI":"10.1007\/s11936-017-0532-8","article-title":"Cardiovascular complications associated with novel Cancer immunotherapies","volume":"19","author":"Jain","year":"2017","journal-title":"Curr. Treat. Options Cardiovasc. Med."},{"key":"10.1016\/j.intimp.2025.115397_bb0230","doi-asserted-by":"crossref","first-page":"66","DOI":"10.3389\/fcvm.2017.00066","article-title":"Radiation-induced cardiovascular disease: A clinical perspective","volume":"4","author":"Yusuf","year":"2017","journal-title":"Front Cardiovasc Med"},{"issue":"11","key":"10.1016\/j.intimp.2025.115397_bb0235","doi-asserted-by":"crossref","first-page":"987","DOI":"10.1056\/NEJMoa1209825","article-title":"Risk of ischemic heart disease in women after radiotherapy for breast cancer","volume":"368","author":"Darby","year":"2013","journal-title":"N. Engl. J. Med."},{"issue":"4","key":"10.1016\/j.intimp.2025.115397_bb0240","doi-asserted-by":"crossref","first-page":"69","DOI":"10.1038\/s41408-021-00459-7","article-title":"CAR-T cell therapy: current limitations and potential strategies","volume":"11","author":"Sterner","year":"2021","journal-title":"Blood Cancer J."},{"issue":"8","key":"10.1016\/j.intimp.2025.115397_bb0245","doi-asserted-by":"crossref","first-page":"1590","DOI":"10.1016\/j.bbmt.2018.05.014","article-title":"Cardiac profile of chimeric antigen receptor T cell therapy in children: A single-institution experience","volume":"24","author":"Burstein","year":"2018","journal-title":"Biol. Blood Marrow Transplant."},{"issue":"25","key":"10.1016\/j.intimp.2025.115397_bb0250","doi-asserted-by":"crossref","first-page":"3099","DOI":"10.1016\/j.jacc.2019.10.038","article-title":"Cardiovascular events among adults treated with chimeric antigen receptor T-cells (CAR-T)","volume":"74","author":"Alvi","year":"2019","journal-title":"J. Am. Coll. Cardiol."},{"issue":"1","key":"10.1016\/j.intimp.2025.115397_bb0255","article-title":"The Warburg effect and mitochondrial oxidative phosphorylation: friends or foes?","volume":"1864","author":"Martins","year":"2023","journal-title":"Biochim. Biophys. Acta Bioenerg."},{"issue":"2","key":"10.1016\/j.intimp.2025.115397_bb0260","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0319442","article-title":"The predictive value of changes in 18F-FDG PET\/CT cardiac uptake patterns and metabolic parameters for anthracycline based chemotherapy induced cardiac toxicity in lymphoma patients","volume":"20","author":"Lin","year":"2025","journal-title":"PloS One"},{"issue":"6","key":"10.1016\/j.intimp.2025.115397_bb0265","doi-asserted-by":"crossref","DOI":"10.3892\/ijo.2022.5357","article-title":"'Reverse Warburg effect' of cancer-associated fibroblasts (review)","volume":"60","author":"Liang","year":"2022","journal-title":"Int. J. Oncol."},{"issue":"1","key":"10.1016\/j.intimp.2025.115397_bb0270","doi-asserted-by":"crossref","first-page":"305","DOI":"10.1038\/s41392-022-01151-3","article-title":"Lactate metabolism in human health and disease","volume":"7","author":"Li","year":"2022","journal-title":"Signal Transduct. Target. Ther."},{"issue":"6","key":"10.1016\/j.intimp.2025.115397_bb0275","doi-asserted-by":"crossref","first-page":"414","DOI":"10.1038\/s41569-022-00698-6","article-title":"Cardio-onco-metabolism: metabolic remodelling in cardiovascular disease and cancer","volume":"19","author":"Karlstaedt","year":"2022","journal-title":"Nat. Rev. Cardiol."},{"issue":"10","key":"10.1016\/j.intimp.2025.115397_bb0280","doi-asserted-by":"crossref","first-page":"124","DOI":"10.1007\/s11538-024-01346-5","article-title":"p53 orchestrates Cancer metabolism: unveiling strategies to reverse the Warburg effect","volume":"86","author":"Abukwaik","year":"2024","journal-title":"Bull. Math. Biol."},{"issue":"34","key":"10.1016\/j.intimp.2025.115397_bb0285","doi-asserted-by":"crossref","first-page":"57813","DOI":"10.18632\/oncotarget.18175","article-title":"The reverse Warburg effect is likely to be an Achilles' heel of cancer that can be exploited for cancer therapy","volume":"8","author":"Fu","year":"2017","journal-title":"Oncotarget"},{"issue":"1","key":"10.1016\/j.intimp.2025.115397_bb0290","doi-asserted-by":"crossref","first-page":"115","DOI":"10.1038\/sj.onc.1203232","article-title":"Ras\/MEK signaling suppresses Myc-dependent apoptosis in cells transformed by c-myc and activated ras","volume":"19","author":"Tsuneoka","year":"2000","journal-title":"Oncogene"},{"key":"10.1016\/j.intimp.2025.115397_bb0295","doi-asserted-by":"crossref","DOI":"10.1016\/j.gene.2021.145796","article-title":"Up-down regulation of HIF-1\u03b1 in cancer progression","volume":"798","author":"Rashid","year":"2021","journal-title":"Gene"},{"issue":"2","key":"10.1016\/j.intimp.2025.115397_bb0300","doi-asserted-by":"crossref","first-page":"202","DOI":"10.1016\/j.jjcc.2022.09.002","article-title":"The roles of HIF-1\u03b1 signaling in cardiovascular diseases","volume":"81","author":"Sato","year":"2023","journal-title":"J. Cardiol."},{"issue":"8","key":"10.1016\/j.intimp.2025.115397_bb0305","doi-asserted-by":"crossref","first-page":"583","DOI":"10.1038\/s41573-024-00979-4","article-title":"Targeting ROS in cancer: rationale and strategies","volume":"23","author":"Glorieux","year":"2024","journal-title":"Nat. Rev. Drug Discov."},{"key":"10.1016\/j.intimp.2025.115397_bb0310","doi-asserted-by":"crossref","first-page":"84","DOI":"10.1016\/j.yjmcc.2023.03.009","article-title":"Cellular reprogramming of fibroblasts in heart regeneration","volume":"180","author":"Chi","year":"2023","journal-title":"J. Mol. Cell. Cardiol."},{"issue":"12","key":"10.1016\/j.intimp.2025.115397_bb0315","doi-asserted-by":"crossref","first-page":"969","DOI":"10.1016\/j.it.2022.10.005","article-title":"Lactic acid and lactate: revisiting the physiological roles in the tumor microenvironment","volume":"43","author":"Apostolova","year":"2022","journal-title":"Trends Immunol."},{"issue":"4","key":"10.1016\/j.intimp.2025.115397_bb0320","doi-asserted-by":"crossref","first-page":"1356","DOI":"10.1007\/s10753-024-01981-z","article-title":"Inhibition of pyruvate dehydrogenase kinase 4 protects cardiomyocytes from lipopolysaccharide-induced mitochondrial damage by reducing lactate accumulation","volume":"47","author":"Chen","year":"2024","journal-title":"Inflammation"},{"issue":"4","key":"10.1016\/j.intimp.2025.115397_bb0325","doi-asserted-by":"crossref","first-page":"H702","DOI":"10.1152\/ajpheart.00231.2022","article-title":"Emerging mitochondrial signaling mechanisms in cardio-oncology: beyond oxidative stress","volume":"323","author":"Bikomeye","year":"2022","journal-title":"Am. J. Physiol. Heart Circ. Physiol."},{"issue":"6","key":"10.1016\/j.intimp.2025.115397_bb0330","doi-asserted-by":"crossref","first-page":"1321","DOI":"10.1158\/1535-7163.MCT-15-0741","article-title":"Trastuzumab, but not Pertuzumab, dysregulates HER2 signaling to mediate inhibition of autophagy and increase in reactive oxygen species production in human cardiomyocytes","volume":"15","author":"Mohan","year":"2016","journal-title":"Mol. Cancer Ther."},{"issue":"8","key":"10.1016\/j.intimp.2025.115397_bb0335","doi-asserted-by":"crossref","first-page":"H1271","DOI":"10.1152\/ajpheart.00517.2014","article-title":"ErbB2 overexpression upregulates antioxidant enzymes, reduces basal levels of reactive oxygen species, and protects against doxorubicin cardiotoxicity","volume":"309","author":"Belmonte","year":"2015","journal-title":"Am. J. Physiol. Heart Circ. Physiol."},{"issue":"1","key":"10.1016\/j.intimp.2025.115397_bb0340","first-page":"22","article-title":"Mechanisms of trastuzumab induced cardiotoxicity - is exercise a potential treatment?","volume":"9","author":"Eaton","year":"2023","journal-title":"Cardiooncology"},{"issue":"10","key":"10.1016\/j.intimp.2025.115397_bb0345","doi-asserted-by":"crossref","first-page":"8337","DOI":"10.3390\/cimb45100526","article-title":"Cardiac toxicities in oncology: elucidating the dark box in the era of precision medicine","volume":"45","author":"Samuel","year":"2023","journal-title":"Curr. Issues Mol. Biol."},{"issue":"1","key":"10.1016\/j.intimp.2025.115397_bb0350","doi-asserted-by":"crossref","first-page":"739","DOI":"10.1186\/s12967-024-05537-5","article-title":"Genetic factors in the pathogenesis of cardio-oncology","volume":"22","author":"Qi","year":"2024","journal-title":"J. Transl. Med."},{"key":"10.1016\/j.intimp.2025.115397_bb0355","doi-asserted-by":"crossref","DOI":"10.1016\/j.cellsig.2025.111637","article-title":"Curcumin chemo-sensitizes intrinsic apoptosis through ROS-mediated mitochondrial hyperpolarization and DNA damage in breast cancer cells","volume":"128","author":"Sarkar","year":"2025","journal-title":"Cell. Signal."},{"issue":"5","key":"10.1016\/j.intimp.2025.115397_bb0360","doi-asserted-by":"crossref","DOI":"10.1038\/cddis.2013.67","article-title":"Targeted therapy of the XIAP\/proteasome pathway overcomes TRAIL-resistance in carcinoma by switching apoptosis signaling to a Bax\/Bak-independent \u2018type I\u2019 mode","volume":"4","author":"Gillissen","year":"2013","journal-title":"Cell Death Dis."},{"issue":"12","key":"10.1016\/j.intimp.2025.115397_bb0365","doi-asserted-by":"crossref","first-page":"1746","DOI":"10.1016\/j.bcp.2010.02.010","article-title":"Different contribution of BH3-only proteins and caspases to doxorubicin-induced apoptosis in p53-deficient leukemia cells","volume":"79","author":"L\u00f3pez-Royuela","year":"2010","journal-title":"Biochem. Pharmacol."},{"issue":"51","key":"10.1016\/j.intimp.2025.115397_bb0370","doi-asserted-by":"crossref","first-page":"19672","DOI":"10.1074\/jbc.RA118.004673","article-title":"Inhibition of cyclin-dependent kinase 2 protects against doxorubicin-induced cardiomyocyte apoptosis and cardiomyopathy","volume":"293","author":"Xia","year":"2018","journal-title":"J. Biol. Chem."},{"key":"10.1016\/j.intimp.2025.115397_bb0375","doi-asserted-by":"crossref","DOI":"10.1016\/j.clinsp.2023.100268","article-title":"Trastuzumab-induced human cardiomyocyte damage through the Notch2\/JAK2\/STAT3 pathway","volume":"78","author":"Su","year":"2023","journal-title":"Clinics (Sao Paulo)"},{"issue":"22","key":"10.1016\/j.intimp.2025.115397_bb0380","doi-asserted-by":"crossref","first-page":"7747","DOI":"10.1158\/1078-0432.CCR-04-0908","article-title":"Trastuzumab down-regulates Bcl-2 expression and potentiates apoptosis induction by Bcl-2\/Bcl-XL bispecific antisense oligonucleotides in HER-2 gene--amplified breast cancer cells","volume":"10","author":"Milella","year":"2004","journal-title":"Clin. Cancer Res."},{"issue":"6","key":"10.1016\/j.intimp.2025.115397_bb0385","doi-asserted-by":"crossref","first-page":"1115","DOI":"10.1158\/1535-7163.MCT-18-0743","article-title":"Neutralization of BCL-2\/X(L) enhances the cytotoxicity of T-DM1 in vivo","volume":"18","author":"Zoeller","year":"2019","journal-title":"Mol. Cancer Ther."},{"issue":"6","key":"10.1016\/j.intimp.2025.115397_bb0390","doi-asserted-by":"crossref","first-page":"647","DOI":"10.1023\/A:1008390429428","article-title":"The contribution of molecular markers to the prediction of response in the treatment of breast cancer: a review of the literature on HER-2, p53 and BCL-2","volume":"11","author":"Hamilton","year":"2000","journal-title":"Ann. Oncol."},{"issue":"9","key":"10.1016\/j.intimp.2025.115397_bb0395","doi-asserted-by":"crossref","DOI":"10.3390\/nu11092090","article-title":"Oxidative stress in cardiovascular diseases: still a therapeutic target?","volume":"11","author":"Senoner","year":"2019","journal-title":"Nutrients"},{"issue":"18","key":"10.1016\/j.intimp.2025.115397_bb0400","doi-asserted-by":"crossref","first-page":"2112","DOI":"10.2174\/1381612827666210125155821","article-title":"Vascular and cardiac oxidative stress and inflammation as targets for Cardioprotection","volume":"27","author":"Daiber","year":"2021","journal-title":"Curr. Pharm. Des."},{"issue":"12","key":"10.1016\/j.intimp.2025.115397_bb0405","doi-asserted-by":"crossref","first-page":"1677","DOI":"10.1093\/jpp\/rgac063","article-title":"Doxorubicin-induced cardiotoxicity: causative factors and possible interventions","volume":"74","author":"Jones","year":"2022","journal-title":"J. Pharm. Pharmacol."},{"issue":"3\u20134","key":"10.1016\/j.intimp.2025.115397_bb0410","doi-asserted-by":"crossref","first-page":"261","DOI":"10.1007\/s10495-022-01711-6","article-title":"Piperlongumine, a piper alkaloid, enhances the efficacy of doxorubicin in breast cancer: involvement of glucose import, ROS, NF-\u03baB and lncRNAs","volume":"27","author":"Awasthee","year":"2022","journal-title":"Apoptosis"},{"issue":"7","key":"10.1016\/j.intimp.2025.115397_bb0415","doi-asserted-by":"crossref","first-page":"758","DOI":"10.1080\/10715762.2019.1628957","article-title":"Ascorbate promotes the cellular accumulation of doxorubicin and reverses the multidrug resistance in breast cancer cells by inducing ROS-dependent ATP depletion","volume":"53","author":"Liu","year":"2019","journal-title":"Free Radic. Res."},{"issue":"1","key":"10.1016\/j.intimp.2025.115397_bb0420","doi-asserted-by":"crossref","first-page":"61","DOI":"10.1186\/s12964-023-01077-5","article-title":"Role of oxidative stress and inflammation-related signaling pathways in doxorubicin-induced cardiomyopathy","volume":"21","author":"Shi","year":"2023","journal-title":"Cell Commun. Signal"},{"key":"10.1016\/j.intimp.2025.115397_bb0425","doi-asserted-by":"crossref","DOI":"10.1016\/j.phymed.2023.154922","article-title":"Amentoflavone mitigates doxorubicin-induced cardiotoxicity by suppressing cardiomyocyte pyroptosis and inflammation through inhibition of the STING\/NLRP3 signalling pathway","volume":"117","author":"Fang","year":"2023","journal-title":"Phytomedicine"},{"key":"10.1016\/j.intimp.2025.115397_bb0430","doi-asserted-by":"crossref","DOI":"10.1016\/j.biopha.2021.112133","article-title":"MCC950 attenuates doxorubicin-induced myocardial injury in vivo and in vitro by inhibiting NLRP3-mediated pyroptosis","volume":"143","author":"Zhang","year":"2021","journal-title":"Biomed. Pharmacother."},{"issue":"10","key":"10.1016\/j.intimp.2025.115397_bb0435","doi-asserted-by":"crossref","first-page":"3449","DOI":"10.1111\/cas.15508","article-title":"Involvement of kallikrein-PAR2-proinflammatory pathway in severe trastuzumab-induced cardiotoxicity","volume":"113","author":"Sasaki","year":"2022","journal-title":"Cancer Sci."},{"key":"10.1016\/j.intimp.2025.115397_bb0440","doi-asserted-by":"crossref","DOI":"10.1016\/j.bcp.2023.115662","article-title":"Trastuzumab potentiates doxorubicin-induced cardiotoxicity via activating the NLRP3 inflammasome in vivo and in vitro","volume":"214","author":"Wei","year":"2023","journal-title":"Biochem. Pharmacol."},{"issue":"4","key":"10.1016\/j.intimp.2025.115397_bb0445","doi-asserted-by":"crossref","first-page":"316","DOI":"10.1093\/eurheartj\/ehab430","article-title":"Targeting early stages of cardiotoxicity from anti-PD1 immune checkpoint inhibitor therapy","volume":"43","author":"Michel","year":"2022","journal-title":"Eur. Heart J."},{"key":"10.1016\/j.intimp.2025.115397_bb0450","doi-asserted-by":"crossref","DOI":"10.1136\/bmj-2023-075859","article-title":"Cardiovascular toxicity of immune therapies for cancer","volume":"385","author":"Palaskas","year":"2024","journal-title":"Bmj"},{"key":"10.1016\/j.intimp.2025.115397_bb0455","doi-asserted-by":"crossref","DOI":"10.1016\/j.smim.2023.101781","article-title":"Pyroptosis-induced inflammation and tissue damage","volume":"69","author":"Vasudevan","year":"2023","journal-title":"Semin. Immunol."},{"issue":"1","key":"10.1016\/j.intimp.2025.115397_bb0460","doi-asserted-by":"crossref","first-page":"6640","DOI":"10.1038\/s41467-024-50996-5","article-title":"Gasdermin-E-mediated pyroptosis drives immune checkpoint inhibitor-associated myocarditis via cGAS-STING activation","volume":"15","author":"Sun","year":"2024","journal-title":"Nat. Commun."},{"key":"10.1016\/j.intimp.2025.115397_bb0465","series-title":"Lin Anqi %J Med Research. Heterogeneity of intratumoral microbiota within the tumor microenvironment and relationship to tumor development[J]","author":"Gao","year":"2025"},{"issue":"5","key":"10.1016\/j.intimp.2025.115397_bb0470","doi-asserted-by":"crossref","first-page":"436","DOI":"10.1007\/s12012-022-09725-x","article-title":"Exploring the pattern of metabolic alterations causing energy imbalance via PPAR\u03b1 dysregulation in cardiac muscle during doxorubicin treatment","volume":"22","author":"Renu","year":"2022","journal-title":"Cardiovasc. Toxicol."},{"key":"10.1016\/j.intimp.2025.115397_bb0475","article-title":"Breviscapine remodels myocardial glucose and lipid metabolism by regulating serotonin to alleviate doxorubicin-induced cardiotoxicity","volume":"13","author":"Li","year":"2022","journal-title":"Front. Pharmacol."},{"issue":"1","key":"10.1016\/j.intimp.2025.115397_bb0480","doi-asserted-by":"crossref","first-page":"255","DOI":"10.1186\/s12944-018-0905-3","article-title":"Dysregulation of cardiac lipid parameters in high-fat high-cholesterol diet-induced rat model","volume":"17","author":"Han","year":"2018","journal-title":"Lipids Health Dis."},{"issue":"4","key":"10.1016\/j.intimp.2025.115397_bb0485","doi-asserted-by":"crossref","first-page":"266","DOI":"10.1038\/s41580-020-00324-8","article-title":"Ferroptosis: mechanisms, biology and role in disease","volume":"22","author":"Jiang","year":"2021","journal-title":"Nat. Rev. Mol. Cell Biol."},{"issue":"9","key":"10.1016\/j.intimp.2025.115397_bb0490","article-title":"Mitochondria-dependent ferroptosis plays a pivotal role in doxorubicin cardiotoxicity. JCI","volume":"5","author":"Tadokoro","year":"2020","journal-title":"Insight"},{"issue":"31","key":"10.1016\/j.intimp.2025.115397_bb0495","doi-asserted-by":"crossref","first-page":"4935","DOI":"10.2174\/0929867331666230719124453","article-title":"Ferroptosis-induced cardiotoxicity and antitumor drugs","volume":"31","author":"Beretta","year":"2024","journal-title":"Curr. Med. Chem."},{"issue":"758","key":"10.1016\/j.intimp.2025.115397_bb0500","doi-asserted-by":"crossref","first-page":"eabn8017","DOI":"10.1126\/scisignal.abn8017","article-title":"Doxorubicin causes ferroptosis and cardiotoxicity by intercalating into mitochondrial DNA and disrupting Alas1-dependent heme synthesis","volume":"15","author":"Abe","year":"2022","journal-title":"Sci. Signal."},{"issue":"2","key":"10.1016\/j.intimp.2025.115397_bb0505","doi-asserted-by":"crossref","DOI":"10.3892\/ijmm.2021.5072","article-title":"Herceptin induces ferroptosis and mitochondrial dysfunction in H9c2 cells","volume":"49","author":"Sun","year":"2022","journal-title":"Int. J. Mol. Med."},{"issue":"1","key":"10.1016\/j.intimp.2025.115397_bb0510","doi-asserted-by":"crossref","first-page":"123","DOI":"10.1186\/s10020-023-00686-7","article-title":"Acetylcholinesterase inhibition protects against trastuzumab-induced cardiotoxicity through reducing multiple programmed cell death pathways","volume":"29","author":"Khuanjing","year":"2023","journal-title":"Mol. Med."},{"issue":"8","key":"10.1016\/j.intimp.2025.115397_bb0515","doi-asserted-by":"crossref","first-page":"599","DOI":"10.1007\/s13238-020-00789-5","article-title":"Cystine transporter SLC7A11\/xCT in cancer: ferroptosis, nutrient dependency, and cancer therapy","volume":"12","author":"Koppula","year":"2021","journal-title":"Protein Cell"},{"issue":"12","key":"10.1016\/j.intimp.2025.115397_bb0520","doi-asserted-by":"crossref","DOI":"10.15252\/emmm.202114351","article-title":"YAP\/TAZ and ATF4 drive resistance to Sorafenib in hepatocellular carcinoma by preventing ferroptosis","volume":"13","author":"Gao","year":"2021","journal-title":"EMBO Mol. Med."},{"issue":"6","key":"10.1016\/j.intimp.2025.115397_bb0525","doi-asserted-by":"crossref","first-page":"1667","DOI":"10.1111\/cns.14130","article-title":"Srs11-92, a ferrostatin-1 analog, improves oxidative stress and neuroinflammation via Nrf2 signal following cerebral ischemia\/reperfusion injury","volume":"29","author":"Chen","year":"2023","journal-title":"CNS Neurosci. Ther."},{"key":"10.1016\/j.intimp.2025.115397_bb0530","doi-asserted-by":"crossref","DOI":"10.1016\/j.redox.2019.101328","article-title":"Insight into the mechanism of ferroptosis inhibition by ferrostatin-1","volume":"28","author":"Miotto","year":"2020","journal-title":"Redox Biol."},{"issue":"3","key":"10.1016\/j.intimp.2025.115397_bb0535","doi-asserted-by":"crossref","first-page":"232","DOI":"10.1021\/acscentsci.7b00028","article-title":"On the mechanism of Cytoprotection by Ferrostatin-1 and Liproxstatin-1 and the role of lipid peroxidation in Ferroptotic cell death","volume":"3","author":"Zilka","year":"2017","journal-title":"ACS Cent. Sci."},{"key":"10.1016\/j.intimp.2025.115397_bb0540","doi-asserted-by":"crossref","DOI":"10.1016\/j.lfs.2022.121207","article-title":"Empagliflozin attenuates trastuzumab-induced cardiotoxicity through suppression of DNA damage and ferroptosis","volume":"312","author":"Min","year":"2023","journal-title":"Life Sci."},{"key":"10.1016\/j.intimp.2025.115397_bb0545","doi-asserted-by":"crossref","DOI":"10.1016\/j.ejphar.2025.177685","article-title":"Targeting mitochondrial dynamics emerges as an effective strategy of cardioprotection against trastuzumab-induced mitochondrial functional aberrations and cardiotoxicity in rats","volume":"999","author":"Maneechote","year":"2025","journal-title":"Eur. J. Pharmacol."},{"issue":"4","key":"10.1016\/j.intimp.2025.115397_bb0550","doi-asserted-by":"crossref","DOI":"10.3892\/ijo.2022.5409","article-title":"Liproxstatin-1 induces cell cycle arrest, apoptosis, and caspase-3\/GSDME-dependent secondary pyroptosis in K562 cells","volume":"61","author":"Dong","year":"2022","journal-title":"Int. J. Oncol."},{"issue":"11\u221212","key":"10.1016\/j.intimp.2025.115397_bb0555","doi-asserted-by":"crossref","first-page":"2195","DOI":"10.1007\/s00018-016-2194-1","article-title":"Mechanisms of ferroptosis","volume":"73","author":"Cao","year":"2016","journal-title":"Cell. Mol. Life Sci."},{"issue":"3","key":"10.1016\/j.intimp.2025.115397_bb0560","doi-asserted-by":"crossref","first-page":"117","DOI":"10.1159\/000375435","article-title":"Warburg effect or reverse Warburg effect? A review of cancer metabolism","volume":"38","author":"Xu","year":"2015","journal-title":"Oncol. Res. Treat."},{"key":"10.1016\/j.intimp.2025.115397_bb0565","doi-asserted-by":"crossref","DOI":"10.1016\/j.mehy.2020.110216","article-title":"From Warburg effect to reverse Warburg effect; the new horizons of anti-cancer therapy","volume":"144","author":"Benny","year":"2020","journal-title":"Med. Hypotheses"},{"issue":"3","key":"10.1016\/j.intimp.2025.115397_bb0570","doi-asserted-by":"crossref","first-page":"242","DOI":"10.1159\/000226569","article-title":"Differences between carnitine derivatives and coenzyme Q10 in preventing in vitro doxorubicin-related cardiac damages","volume":"45","author":"Neri","year":"1988","journal-title":"Oncology"},{"issue":"2","key":"10.1016\/j.intimp.2025.115397_bb0575","doi-asserted-by":"crossref","first-page":"18","DOI":"10.1007\/s11864-020-00812-1","article-title":"Metabolic aspects of anthracycline cardiotoxicity","volume":"22","author":"Russo","year":"2021","journal-title":"Curr. Treat. Options Oncol."},{"issue":"5","key":"10.1016\/j.intimp.2025.115397_bb0580","doi-asserted-by":"crossref","first-page":"655","DOI":"10.1016\/j.jaccao.2024.07.016","article-title":"Anthracycline cardiotoxicity in adult Cancer patients: JACC: CardioOncology state-of-the-art review","volume":"6","author":"Camilli","year":"2024","journal-title":"JACC CardioOncol"},{"issue":"36","key":"10.1016\/j.intimp.2025.115397_bb0585","doi-asserted-by":"crossref","first-page":"2768","DOI":"10.1093\/eurheartj\/ehw211","volume":"37","author":"Zamorano","year":"2016","journal-title":"Eur. Heart J."},{"issue":"4","key":"10.1016\/j.intimp.2025.115397_bb0590","doi-asserted-by":"crossref","first-page":"249","DOI":"10.1080\/14779072.2018.1443394","article-title":"Cardio-oncology: the role of advanced echocardiography in cancer patients","volume":"16","author":"Venneri","year":"2018","journal-title":"Expert Rev. Cardiovasc. Ther."},{"issue":"1","key":"10.1016\/j.intimp.2025.115397_bb0595","doi-asserted-by":"crossref","first-page":"R33","DOI":"10.1530\/ERP-17-0013","article-title":"Cardio-oncology: what you need to know now for clinical practice and echocardiography","volume":"4","author":"Larsen","year":"2017","journal-title":"Echo Res Pract"},{"issue":"3","key":"10.1016\/j.intimp.2025.115397_bb0600","doi-asserted-by":"crossref","first-page":"610","DOI":"10.21037\/cdt-20-165","article-title":"The use of cardiovascular magnetic resonance as an early non-invasive biomarker for cardiotoxicity in cardio-oncology","volume":"10","author":"Burrage","year":"2020","journal-title":"Cardiovasc Diagn Ther"},{"issue":"1","key":"10.1016\/j.intimp.2025.115397_bb0605","doi-asserted-by":"crossref","first-page":"121","DOI":"10.1016\/j.hfc.2020.08.009","article-title":"The role of cardiovascular MRI in cardio-oncology","volume":"17","author":"Bottinor","year":"2021","journal-title":"Heart Fail. Clin."},{"issue":"2","key":"10.1016\/j.intimp.2025.115397_bb0610","doi-asserted-by":"crossref","first-page":"191","DOI":"10.1016\/j.jaccao.2021.04.011","article-title":"Cardiac magnetic resonance in cardio-oncology: advantages, importance of expediency, and considerations to navigate pre-authorization","volume":"3","author":"O\u2019Quinn","year":"2021","journal-title":"JACC CardioOncol"},{"issue":"1","key":"10.1016\/j.intimp.2025.115397_bb0615","first-page":"17","article-title":"Anthracycline cardiotoxicity: current methods of diagnosis and possible role of (18)F-FDG PET\/CT as a new biomarker","volume":"9","author":"Becker","year":"2023","journal-title":"Cardiooncology"},{"issue":"11","key":"10.1016\/j.intimp.2025.115397_bb0620","doi-asserted-by":"crossref","first-page":"1442","DOI":"10.1007\/s11912-024-01598-3","article-title":"Clinical applications and advancements of positron emission tomography\/computed tomography in cardio-oncology: A comprehensive literature review and emerging perspectives","volume":"26","author":"Battisha","year":"2024","journal-title":"Curr. Oncol. Rep."},{"issue":"8","key":"10.1016\/j.intimp.2025.115397_bb0625","doi-asserted-by":"crossref","first-page":"1173","DOI":"10.1016\/j.jcmg.2018.06.003","article-title":"Multi-modality imaging in the assessment of cardiovascular toxicity in the Cancer patient[J]","volume":"11","author":"Plana","year":"2018","journal-title":"JACC Cardiovasc. Imaging"},{"key":"10.1016\/j.intimp.2025.115397_bb0630","first-page":"15","article-title":"Artificial intelligence and imaging: opportunities in cardio-oncology","author":"Madan","year":"2022","journal-title":"Am Heart J Plus"},{"issue":"2","key":"10.1016\/j.intimp.2025.115397_bb0635","doi-asserted-by":"crossref","first-page":"150","DOI":"10.5603\/KP.a2016.0163","article-title":"Tissue Doppler echocardiography detects subclinical left ventricular dysfunction in patients undergoing chemotherapy for colon cancer: insights from ONCOECHO multicentre study","volume":"75","author":"P\u0142o\u0144ska-Go\u015bciniak","year":"2017","journal-title":"Kardiol. Pol."},{"issue":"5","key":"10.1016\/j.intimp.2025.115397_bb0640","doi-asserted-by":"crossref","first-page":"682","DOI":"10.1002\/ejhf.806","article-title":"Immune-related fulminant myocarditis in a patient receiving ipilimumab therapy for relapsed chronic myelomonocytic leukaemia","volume":"19","author":"Berg","year":"2017","journal-title":"Eur. J. Heart Fail."},{"issue":"12","key":"10.1016\/j.intimp.2025.115397_bb0645","doi-asserted-by":"crossref","first-page":"1524","DOI":"10.1002\/ejhf.670","article-title":"Resting heart rate is an independent predictor of death in patients with colorectal, pancreatic, and non-small cell lung cancer: results of a prospective cardiovascular long-term study","volume":"18","author":"Anker","year":"2016","journal-title":"Eur. J. Heart Fail."},{"issue":"25","key":"10.1016\/j.intimp.2025.115397_bb0650","doi-asserted-by":"crossref","first-page":"3910","DOI":"10.1200\/JCO.2009.27.3615","article-title":"Trastuzumab-induced cardiotoxicity: clinical and prognostic implications of troponin I evaluation","volume":"28","author":"Cardinale","year":"2010","journal-title":"J. Clin. Oncol."},{"issue":"6","key":"10.1016\/j.intimp.2025.115397_bb0655","doi-asserted-by":"crossref","first-page":"715","DOI":"10.1016\/j.leukres.2011.01.018","article-title":"NT-proBNP: a cardiac biomarker to assess prognosis in non-Hodgkin lymphoma","volume":"35","author":"Gimeno","year":"2011","journal-title":"Leuk. Res."},{"issue":"11","key":"10.1016\/j.intimp.2025.115397_bb0660","doi-asserted-by":"crossref","first-page":"1966","DOI":"10.1002\/ejhf.2017","article-title":"Role of serum biomarkers in cancer patients receiving cardiotoxic cancer therapies: a position statement from the cardio-oncology study Group of the Heart Failure Association and the cardio-oncology Council of the European Society of cardiology","volume":"22","author":"Pudil","year":"2020","journal-title":"Eur. J. Heart Fail."},{"key":"10.1016\/j.intimp.2025.115397_bb0665","series-title":"Gu Qiqi %J Med Research. Optimized Dynamic Network Biomarker Deciphers a High-Resolution Heterogeneity Within Thyroid Cancer Molecular Subtypes[J]","author":"Haonan","year":"2025"},{"issue":"7","key":"10.1016\/j.intimp.2025.115397_bb0670","doi-asserted-by":"crossref","first-page":"52","DOI":"10.1007\/s11886-018-1002-y","article-title":"Biomarker discovery in cardio-oncology","volume":"20","author":"Vohra","year":"2018","journal-title":"Curr. Cardiol. Rep."},{"issue":"6","key":"10.1016\/j.intimp.2025.115397_bb0675","doi-asserted-by":"crossref","first-page":"715","DOI":"10.1002\/ejhf.1494","article-title":"Heart failure Association of the European Society of cardiology practical guidance on the use of natriuretic peptide concentrations","volume":"21","author":"Mueller","year":"2019","journal-title":"Eur. J. Heart Fail."},{"issue":"2","key":"10.1016\/j.intimp.2025.115397_bb0680","doi-asserted-by":"crossref","first-page":"350","DOI":"10.1002\/ejhf.1631","article-title":"Troponins and brain natriuretic peptides for the prediction of cardiotoxicity in cancer patients: a meta-analysis","volume":"22","author":"Michel","year":"2020","journal-title":"Eur. J. Heart Fail."},{"issue":"6","key":"10.1016\/j.intimp.2025.115397_bb0685","doi-asserted-by":"crossref","first-page":"699","DOI":"10.1016\/j.jacbts.2023.04.004","article-title":"The emerging role of circular RNAs in cardio-oncology","volume":"8","author":"Gao","year":"2023","journal-title":"JACC Basic Transl Sci"},{"issue":"11","key":"10.1016\/j.intimp.2025.115397_bb0690","doi-asserted-by":"crossref","first-page":"1805","DOI":"10.1093\/cvr\/cvaa195","article-title":"Non-coding RNAs: update on mechanisms and therapeutic targets from the ESC working groups of myocardial function and cellular biology of the heart","volume":"116","author":"B\u00e4r","year":"2020","journal-title":"Cardiovasc. Res."},{"issue":"Suppl. 1","key":"10.1016\/j.intimp.2025.115397_bb0695","doi-asserted-by":"crossref","first-page":"S95","DOI":"10.1016\/j.thromres.2021.12.017","article-title":"Cardiovascular toxic effects of antitumor agents: Pathogenetic mechanisms","volume":"213","author":"Pantazi","year":"2022","journal-title":"Thromb. Res."},{"issue":"1","key":"10.1016\/j.intimp.2025.115397_bb0700","doi-asserted-by":"crossref","first-page":"91","DOI":"10.1007\/s10741-018-9731-y","article-title":"Cardio-oncology: a new and developing sector of research and therapy in the field of cardiology","volume":"24","author":"Kostakou","year":"2019","journal-title":"Heart Fail. Rev."},{"issue":"3","key":"10.1016\/j.intimp.2025.115397_bb0705","first-page":"253","article-title":"Cardio-oncology: the intersection between cardiovascular disease and Cancer","volume":"12","author":"Coviello","year":"2021","journal-title":"J. Adv. Pract. Oncol."},{"issue":"9","key":"10.1016\/j.intimp.2025.115397_bb0710","doi-asserted-by":"crossref","first-page":"1302","DOI":"10.1161\/CIRCRESAHA.117.310782","article-title":"Emerging role of precision medicine in cardiovascular disease","volume":"122","author":"Leopold","year":"2018","journal-title":"Circ. Res."},{"issue":"5","key":"10.1016\/j.intimp.2025.115397_bb0715","doi-asserted-by":"crossref","first-page":"679","DOI":"10.1007\/s11864-024-01203-6","article-title":"Precision cardio-oncology: update on omics-based diagnostic methods","volume":"25","author":"Kuang","year":"2024","journal-title":"Curr. Treat. Options Oncol."},{"issue":"2","key":"10.1016\/j.intimp.2025.115397_bb0720","doi-asserted-by":"crossref","DOI":"10.3892\/mmr.2020.11752","article-title":"The mRNA expression of Il6 and Pdcd1 are predictive and protective factors for doxorubicin-induced cardiotoxicity","volume":"23","author":"Kanno","year":"2021","journal-title":"Mol. Med. Rep."},{"issue":"1","key":"10.1016\/j.intimp.2025.115397_bb0725","doi-asserted-by":"crossref","first-page":"337","DOI":"10.1007\/s10741-020-09987-z","article-title":"Pathogenesis of chronic heart failure: cardiovascular aging, risk factors, comorbidities, and disease modifiers","volume":"27","author":"Triposkiadis","year":"2022","journal-title":"Heart Fail. Rev."},{"issue":"5","key":"10.1016\/j.intimp.2025.115397_bb0730","doi-asserted-by":"crossref","first-page":"935","DOI":"10.1093\/cvr\/cvz018","article-title":"hiPSCs in cardio-oncology: deciphering the genomics","volume":"115","author":"Pinheiro","year":"2019","journal-title":"Cardiovasc. Res."},{"issue":"1","key":"10.1016\/j.intimp.2025.115397_bb0735","doi-asserted-by":"crossref","DOI":"10.1161\/CIRCGEN.117.001753","article-title":"Chemotherapy-related cardiac dysfunction: A systematic review of genetic variants modulating individual risk","volume":"11","author":"Linschoten","year":"2018","journal-title":"Circ Genom Precis Med"},{"key":"10.1016\/j.intimp.2025.115397_bb0740","doi-asserted-by":"crossref","DOI":"10.1016\/j.biopha.2022.113280","article-title":"ATF4 protects against sorafenib-induced cardiotoxicity by suppressing ferroptosis","volume":"153","author":"Jiang","year":"2022","journal-title":"Biomed. Pharmacother."},{"issue":"11","key":"10.1016\/j.intimp.2025.115397_bb0745","doi-asserted-by":"crossref","first-page":"1639","DOI":"10.1038\/nm.2919","article-title":"Identification of the molecular basis of doxorubicin-induced cardiotoxicity","volume":"18","author":"Zhang","year":"2012","journal-title":"Nat. Med."},{"issue":"6","key":"10.1016\/j.intimp.2025.115397_bb0750","doi-asserted-by":"crossref","first-page":"685","DOI":"10.1007\/s00392-019-01557-0","article-title":"The potential prognostic utility of salivary galectin-3 concentrations in heart failure","volume":"109","author":"Zhang","year":"2020","journal-title":"Clin. Res. Cardiol."},{"issue":"5","key":"10.1016\/j.intimp.2025.115397_bb0755","doi-asserted-by":"crossref","first-page":"1112","DOI":"10.1536\/ihj.20-809","article-title":"Circ-SKA3 enhances doxorubicin toxicity in AC16 cells through miR-1303\/TLR4 Axis","volume":"62","author":"Li","year":"2021","journal-title":"Int. Heart J."},{"issue":"41","key":"10.1016\/j.intimp.2025.115397_bb0760","doi-asserted-by":"crossref","first-page":"4229","DOI":"10.1093\/eurheartj\/ehac244","article-title":"2022 ESC guidelines on cardio-oncology developed in collaboration with the European Hematology Association (EHA), the European Society for Therapeutic Radiology and Oncology (ESTRO) and the international cardio-oncology society (IC-OS)","volume":"43","author":"Lyon","year":"2022","journal-title":"Eur. Heart J."},{"key":"10.1016\/j.intimp.2025.115397_bb0765","doi-asserted-by":"crossref","first-page":"503","DOI":"10.1146\/annurev-physiol-031620-095920","article-title":"Effects of SGLT2 inhibitors on kidney and cardiovascular function","volume":"83","author":"Vallon","year":"2021","journal-title":"Annu. Rev. Physiol."},{"issue":"12","key":"10.1016\/j.intimp.2025.115397_bb0770","doi-asserted-by":"crossref","first-page":"761","DOI":"10.1038\/s41569-020-0406-8","article-title":"SGLT2 inhibitors: mechanisms of cardiovascular benefit beyond glycaemic control","volume":"17","author":"Cowie","year":"2020","journal-title":"Nat. Rev. Cardiol."},{"issue":"3","key":"10.1016\/j.intimp.2025.115397_bb0775","article-title":"Cancer-therapy-related cardiac dysfunction: latest advances in prevention and treatment","volume":"15","author":"Contaldi","year":"2025","journal-title":"Life (Basel)"},{"issue":"10","key":"10.1016\/j.intimp.2025.115397_bb0780","doi-asserted-by":"crossref","first-page":"1328","DOI":"10.1136\/ard-2023-224242","article-title":"SGLT2 inhibitors alleviated podocyte damage in lupus nephritis by decreasing inflammation and enhancing autophagy","volume":"82","author":"Zhao","year":"2023","journal-title":"Ann. Rheum. Dis."},{"issue":"1","key":"10.1016\/j.intimp.2025.115397_bb0785","volume":"2","author":"Teresa","year":"2023","journal-title":"Strategies for risk stratification and cardiovascular toxicity prevention in patients with cancer[J]"},{"issue":"2","key":"10.1016\/j.intimp.2025.115397_bb0790","doi-asserted-by":"crossref","first-page":"159","DOI":"10.1016\/j.jaccao.2024.01.007","article-title":"The Cardioprotective and anticancer effects of SGLT2 inhibitors: JACC: CardioOncology state-of-the-art review","volume":"6","author":"Dabour","year":"2024","journal-title":"JACC CardioOncol"},{"key":"10.1016\/j.intimp.2025.115397_bb0795","doi-asserted-by":"crossref","DOI":"10.1136\/bmj-2023-078242","article-title":"Effect of combination treatment with glucagon-like peptide-1 receptor agonists and sodium-glucose cotransporter-2 inhibitors on incidence of cardiovascular and serious renal events: population based cohort study","volume":"385","author":"Simms-Williams","year":"2024","journal-title":"Bmj"},{"issue":"1","key":"10.1016\/j.intimp.2025.115397_bb0800","doi-asserted-by":"crossref","first-page":"866","DOI":"10.1186\/s12885-023-11353-9","article-title":"Acute and early-onset cardiotoxicity in children and adolescents with cancer: a systematic review","volume":"23","author":"Kouwenberg","year":"2023","journal-title":"BMC Cancer"},{"issue":"1","key":"10.1016\/j.intimp.2025.115397_bb0805","article-title":"Diagnosis and Management of Cancer Treatment-Related Cardiac Dysfunction and Heart Failure in children","volume":"10","author":"Hegazy","year":"2023","journal-title":"Children (Basel)"},{"issue":"1","key":"10.1016\/j.intimp.2025.115397_bb0810","doi-asserted-by":"crossref","first-page":"38","DOI":"10.1186\/s13293-018-0198-2","article-title":"Clinical and preclinical evidence of sex-related differences in anthracycline-induced cardiotoxicity","volume":"9","author":"Meiners","year":"2018","journal-title":"Biol. Sex Differ."},{"issue":"5","key":"10.1016\/j.intimp.2025.115397_bb0815","doi-asserted-by":"crossref","first-page":"564","DOI":"10.1016\/j.hlc.2024.01.011","article-title":"Integrating cardio-oncology across the research pipeline, policy, and practice in Australia-An Australian cardiovascular Alliance perspective","volume":"33","author":"Singleton","year":"2024","journal-title":"Heart Lung Circ."},{"issue":"1","key":"10.1016\/j.intimp.2025.115397_bb0820","doi-asserted-by":"crossref","first-page":"3","DOI":"10.1007\/s00395-024-01080-y","article-title":"Cardio-oncology: chances and challenges","volume":"120","author":"Vi\u00f1as-Mendieta","year":"2025","journal-title":"Basic Res. Cardiol."},{"issue":"8","key":"10.1016\/j.intimp.2025.115397_bb0825","doi-asserted-by":"crossref","first-page":"705","DOI":"10.1016\/j.jacbts.2021.05.008","article-title":"Cardio-oncology: understanding the intersections between cardiac metabolism and Cancer biology","volume":"6","author":"Karlstaedt","year":"2021","journal-title":"JACC Basic Transl Sci"},{"issue":"2","key":"10.1016\/j.intimp.2025.115397_bb0830","doi-asserted-by":"crossref","first-page":"256","DOI":"10.1016\/j.jaccao.2019.11.007","article-title":"Proceedings from the global cardio-oncology summit: the top 10 priorities to actualize for CardioOncology","volume":"1","author":"Lenihan","year":"2019","journal-title":"JACC CardioOncol"}],"container-title":["International Immunopharmacology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1567576925013888?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1567576925013888?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,3,7]],"date-time":"2026-03-07T13:48:20Z","timestamp":1772891300000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1567576925013888"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,10]]},"references-count":166,"alternative-id":["S1567576925013888"],"URL":"https:\/\/doi.org\/10.1016\/j.intimp.2025.115397","relation":{},"ISSN":["1567-5769"],"issn-type":[{"value":"1567-5769","type":"print"}],"subject":[],"published":{"date-parts":[[2025,10]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Cancer therapy\u2013induced cardiac metabolic reprogramming: A new frontier in cardio-oncology","name":"articletitle","label":"Article Title"},{"value":"International Immunopharmacology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.intimp.2025.115397","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2025 Elsevier B.V. All rights are reserved, including those for text and data mining, AI training, and similar technologies.","name":"copyright","label":"Copyright"}],"article-number":"115397"}}